Price (delayed)
$2.6888
Market cap
$4.41M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.54
Enterprise value
$4.09M
Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12
There are no recent dividends present for TCRT.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.